Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Why Iovance Is Up Nearly 11% Today
04:27pm, Wednesday, 15'th Sep 2021
Investors are starting to connect some drug development dots... with a little help.
Cathie Wood's ARK Invest Sells Over 300,000 Shares of Iovance Bio
08:45am, Friday, 27'th Aug 2021
One of the ARK exchange-traded funds run by ETF star Cathie Wood made huge sale on Thursday.
Cathie Wood's ARK Invest Sells Over 125,000 Shares of Iovance Bio
08:45am, Thursday, 26'th Aug 2021
One of the ARK exchange-traded funds run by ETF star Cathie Wood made huge sale on Wednesday.
2 Beaten-Down Biotech Stocks: Are They Bargains Now?
06:31am, Tuesday, 17'th Aug 2021
These drugmakers delivered some upsetting news, but was it really so bad?
Implied Volatility Surging for Iovance (IOVA) Stock Options
09:55am, Monday, 16'th Aug 2021
Investors need to pay close attention to Iovance (IOVA) stock based on the movements in the options market lately.
Iovance (IOVA) Q2 Earnings Miss Estimates, Pipeline in Focus
10:44am, Friday, 06'th Aug 2021
Iovance's (IOVA) second-quarter loss is wider than expected. The company is progressing well in terms of development of its pipeline candidates.
Iovance Biotherapeutics, Inc. (IOVA) CEO Frederick Vogt on Q2 2021 Results - Earnings Call Transcript
10:45pm, Thursday, 05'th Aug 2021
Iovance Biotherapeutics, Inc. (IOVA) CEO Frederick Vogt on Q2 2021 Results - Earnings Call Transcript
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 5, 2021
04:30pm, Monday, 19'th Jul 2021
SAN CARLOS, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report
Why Iovance Biotherapeutics Soared 40% In June
02:24am, Thursday, 08'th Jul 2021
The biopharma outfit has put some red flags in the rearview mirror, and sees a plausible approval on the horizon.
Iovance (IOVA) Announces Lung Cancer Study Data on TIL Therapy
11:03am, Wednesday, 30'th Jun 2021
Iovance (IOVA) is developing several TIL therapies, including LN-145, in a mid-stage study. Data from the lung cancer cohort evaluating LN-145 monotherapy demonstrates an ORR of 21.4%.
SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced t
Iovance Biotherapeutics' TIL Therapy Achieves ORR Of 21.4% In Pre-Treated Lung Cancer Patients
09:12am, Tuesday, 29'th Jun 2021
Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced clinical data for its tumor-infiltrating lymphocyte (TIL) therapy LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC).
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer
06:30am, Tuesday, 29'th Jun 2021
21.4% Overall Response Rate (ORR) in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients Following One or More Prior Systemic Therapies Including Immunotherapy
Should You Buy This Cathie Wood Biotech Stock?
07:39am, Thursday, 17'th Jun 2021
This biotech's fumble has caught the attention of a fund manager known for making innovative investments.
Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting
09:24am, Sunday, 06'th Jun 2021
Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study
